Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
baricitinib + dexamethasone
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Baricitinib + dexamethasone is a combination therapy that has been studied for the treatment of COVID-19. Both drugs have anti-inflammatory properties but work through different mechanisms. Baricitinib is a JAK inhibitor that blocks inflammatory cytokine signaling, while dexamethasone is a glucocorticoid that suppresses inflammatory responses. Clinical trials have compared the efficacy and safety of these drugs when used individually in combination with remdesivir, but the combination of both drugs together has shown potential for improving outcomes in hospitalized COVID-19 patients with severe disease.
02
Targets
Beyond the preview
Go deeper on baricitinib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on baricitinib + dexamethasone.